**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | TORY 120 TABLETS | | REF. NO: NDQD201507012 |
| **DATE RECEIVED:** 07.07.2015 | **LABEL CLAIM:** | Each film coated tablet contains Etoricoxib INN 120mg | |
| **BATCH NO.:** 504001 | **PRESENTATION:** | white flavored powder for reconstitution in 100ml amber bottle inside a unit box. | |
| **MGF. DATE:** Apr. 2015 | **MANUFACTURER:** | SQUARE Pharmaceuticals Ltd. | |
| **EXP. DATE:** Mar. 2017 | **ADDRESS:** | BANGLADESH. | |
| **CLIENT REF NO:** | **CLIENT:** | Ace Pharmaceuticals Ltd P.O BOX 29787-00202 Nairobi KENYA | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol .V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | In - House Method | RT of the major peak in the assay sample preparation corresponds to that in the assay standard preparation | Super-imposable peak at RT 6.9Ã‚Â± 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | UV | In - House Method | No Tablet Less than 80% [n=6] | 92.7% (RSD=1.5%,n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | UV | In - House Method | No Tablet Less than 80% [n=6] |  | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | In - House Method | 90.0% - 110% | 99.3% (RSD=0.3%; n=9) | **COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. J. CHEPCHUMBA |  | DATE:25-09-2015 |
| ANALYST: | DR. G. WANG'ANG'A |  | DATE:12-10-2015 |
| ANALYST: | NICHOLAS MWAURA |  | DATE:10-22-2015 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:10-26-2015 |